La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Yuhan Croissance future

Future contrôle des critères 2/6

Yuhan devrait augmenter ses bénéfices et son chiffre d'affaires de 24.1% et de 9.8% par an respectivement. Le BPA devrait croître de de 24% par an. Le rendement des capitaux propres devrait être 9.4% dans 3 ans.

Informations clés

21.2%

Taux de croissance des bénéfices

21.1%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	38.0%
Taux de croissance des recettes	10.0%
Rendement futur des capitaux propres	9.6%
Couverture par les analystes	Good
Dernière mise à jour	21 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Jul 01

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 13

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

May 13

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Mar 11

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

May 01

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Apr 16

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Mar 15

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Feb 25

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Feb 10

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

Jan 28

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Jan 13

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Nov 20

Prévisions de croissance des bénéfices et des revenus

KOSE:A000100 - Estimations futures des analystes et données financières antérieures (KRW Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	2,442,765	243,356	262,891	284,625	15
12/31/2025	2,282,504	208,388	190,290	214,671	17
12/31/2024	2,066,704	157,411	127,000	164,800	15
6/30/2024	1,893,119	147,849	-75,289	100,417	N/A
3/31/2024	1,860,529	124,466	-80,670	110,014	N/A
12/31/2023	1,858,984	133,993	-59,775	144,128	N/A
9/30/2023	1,872,336	88,109	-59,302	113,301	N/A
6/30/2023	1,820,811	76,045	-94,824	48,972	N/A
3/31/2023	1,808,041	101,446	-18,662	106,905	N/A
12/31/2022	1,775,847	95,144	-2,356	99,529	N/A
9/30/2022	1,749,315	74,669	21,500	112,004	N/A
6/30/2022	1,769,245	97,836	64,662	146,027	N/A
3/31/2022	1,719,630	97,911	-77,146	1,983	N/A
12/31/2021	1,687,810	102,583	17,726	99,000	N/A
9/30/2021	1,725,261	98,128	-40,214	63,556	N/A
6/30/2021	1,703,475	97,833	-90,028	16,218	N/A
3/31/2021	1,685,623	97,578	33,086	125,628	N/A
12/31/2020	1,619,865	192,761	-55,854	28,830	N/A
9/30/2020	1,552,188	184,730	-12,076	40,572	N/A
6/30/2020	1,504,765	168,667	95,017	136,587	N/A
3/31/2020	1,448,677	140,227	-32,349	12,995	N/A
12/31/2019	1,480,354	40,006	19,251	65,985	N/A
9/30/2019	1,500,782	44,230	22,262	71,414	N/A
6/30/2019	1,497,130	41,438	-43,955	1,332	N/A
3/31/2019	1,523,954	52,333	109,427	156,727	N/A
12/31/2018	1,518,823	57,481	45,602	93,452	N/A
9/30/2018	1,481,906	70,146	54,109	108,573	N/A
6/30/2018	1,482,034	84,572	48,987	107,587	N/A
3/31/2018	1,450,870	100,288	N/A	112,160	N/A
12/31/2017	1,462,248	109,034	N/A	126,125	N/A
9/30/2017	1,434,749	139,325	N/A	116,234	N/A
6/30/2017	1,417,835	137,434	N/A	135,085	N/A
3/31/2017	1,395,518	139,440	N/A	142,224	N/A
12/31/2016	1,320,797	161,249	N/A	74,144	N/A
9/30/2016	1,274,011	134,997	N/A	98,827	N/A
6/30/2016	1,223,925	155,819	N/A	97,292	N/A
3/31/2016	1,163,130	152,682	N/A	88,684	N/A
12/31/2015	1,128,731	126,047	N/A	126,235	N/A
9/30/2015	1,097,229	118,104	N/A	120,389	N/A
6/30/2015	1,046,716	98,362	N/A	140,058	N/A
3/31/2015	1,031,875	94,628	N/A	71,402	N/A
12/31/2014	1,017,492	90,948	N/A	94,386	N/A
9/30/2014	1,007,109	95,434	N/A	78,642	N/A
6/30/2014	970,253	87,696	N/A	44,515	N/A
3/31/2014	953,191	83,863	N/A	56,486	N/A
12/31/2013	943,609	86,461	N/A	79,778	N/A
9/30/2013	879,997	85,032	N/A	86,196	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de A000100 ( 24.1% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de A000100 ( 24.1% par an) devraient croître plus lentement que le marché KR ( 28.5% par an).

Croissance élevée des bénéfices: Les bénéfices de A000100 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de A000100 ( 9.8% par an) devrait croître plus lentement que le marché de KR ( 10.5% par an).

Croissance élevée des revenus: Le chiffre d'affaires de A000100 ( 9.8% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de A000100 devrait être faible dans 3 ans ( 9.4 %).

Yuhan Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 7.1% to ₩99,222

Consensus revenue estimates increase by 28%

Consensus EPS estimates increase by 37%, revenue downgraded

Price target increased by 7.8% to ₩80,222

Consensus EPS estimates fall by 11%

Consensus forecasts updated

Recent updates

Price target increased by 7.1% to ₩99,222

Investor sentiment deteriorates as stock falls 15%

Now 20% undervalued

Investor sentiment improves as stock rises 15%

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Investor sentiment improves as stock rises 19%

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Consensus revenue estimates increase by 28%

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

Now 22% overvalued after recent price rise

Full year 2023 earnings released: EPS: ₩1,815 (vs ₩1,267 in FY 2022)

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Investor sentiment improves as stock rises 18%

Insufficient new directors

Now 21% undervalued

Upcoming dividend of ₩381 per share at 0.6% yield

Consensus EPS estimates increase by 37%, revenue downgraded

Investor sentiment deteriorates as stock falls 23%

Now 24% undervalued

Price target increased by 7.8% to ₩80,222

First quarter 2023 earnings released: EPS: ₩311 (vs ₩222 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

Upcoming dividend of ₩381 per share

Consensus EPS estimates fall by 11%

Now 20% undervalued

Full year 2021 earnings: EPS and revenues miss analyst expectations

Yuhan Corporation (KOSE:A000100) announces an Equity Buyback for KRW 20,000 million worth of its shares.

Upcoming dividend of ₩381 per share

Third quarter 2021 earnings released: EPS ₩470 (vs ₩464 in 3Q 2020)

First quarter 2021 earnings released: EPS ₩315 (vs ₩1,768 in 1Q 2020)

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

Consensus forecasts updated

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Full year 2020 earnings released: EPS ₩2,943 (vs ₩610 in FY 2019)

New 90-day low: ₩60,700

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Yuhan Corporation, Annual General Meeting, Mar 19, 2021

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

New 90-day high: ₩75,100

Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

New 90-day high: ₩75,100

Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

New 90-day high: ₩72,300

Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Price target raised to ₩72,704

Price target raised to ₩67,579

Yuhan Corporation and Sorrento Therapeutics, Inc. Announces Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

New 90-day high: ₩72,000

Price target raised to ₩63,148

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance